Applied Molecular Transport (AMT) is a privately held venture-backed, clinical-stage biopharmaceutical company that is applying its proprietary bioengineering technology platforms to create transformative oral biological therapies for patients with severe autoimmune, inflammatory, liver and metabolic diseases. Learn More

 

Privileged Access to GI Immunology and Convergent Pathways

Learn More

Changing the Paradigm for Biologics
 

Learn More

News:

Sep 
09, 
2019

Applied Molecular Transport Debuts with First Patient Dosed in Phase 1b Clinical Trial of AMT-101 in Adults with Ulcerative Colitis | Learn More

Events:

No events scheduled at this time.